These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

999 related articles for article (PubMed ID: 33287875)

  • 21. A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
    Andrea AE; Chiron A; Sarrabayrouse G; Bessoles S; Hacein-Bey-Abina S
    Front Immunol; 2024; 15():1459818. PubMed ID: 39430751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
    Ruppel KE; Fricke S; Köhl U; Schmiedel D
    Front Immunol; 2022; 13():822298. PubMed ID: 35371071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
    Zhuang X; Long EO
    Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.
    Wang L; Dou M; Ma Q; Yao R; Liu J
    Int Immunopharmacol; 2019 Sep; 74():105695. PubMed ID: 31254958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response.
    Cienfuegos-Jimenez O; Vazquez-Garza E; Rojas-Martinez A
    Curr Gene Ther; 2022; 22(4):303-318. PubMed ID: 34923939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
    Zhao Y; Zhou X
    Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reprogramming natural killer cells for cancer therapy.
    Wang K; Wang L; Wang Y; Xiao L; Wei J; Hu Y; Wang D; Huang H
    Mol Ther; 2024 Sep; 32(9):2835-2855. PubMed ID: 38273655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.
    McErlean EM; McCarthy HO
    J Nanobiotechnology; 2024 Sep; 22(1):552. PubMed ID: 39256765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in CAR-NK cell therapy for hematological malignancies.
    Yang R; Yang Y; Liu R; Wang Y; Yang R; He A
    Front Immunol; 2024; 15():1414264. PubMed ID: 39007146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.
    Daher M; Rezvani K
    Curr Opin Immunol; 2018 Apr; 51():146-153. PubMed ID: 29605760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
    Li Y; Hermanson DL; Moriarity BS; Kaufman DS
    Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.